Hims & Hers Health (NYSE: HIMS) is a telehealth company that went public through a special purpose acquisition company in 2021. Through a subscription model, it helps provide patients with access to medications they need. It focuses on sensitive areas of healthcare, including erectile dysfunction and hair loss.

That strategy has been paying off as Hims & Hers has been growing its top line and shrinking its losses in recent years. The big question is, where will the business be five years from now, and is it worth buying and holding the stock until then?

Hims & Hers has been focusing on niche areas of healthcare but for the business to continue growing, it will need to diversify. And the company is doing that already. Recently, it announced an expansion into cardiovascular health.

Continue reading

Source Fool.com